Xiaoying Shen

Associate Professor in Surgery

Surgery, Surgical Sciences

sxshen@duke.edu

Box 2926 DUMC, Durham, NC 27710

205 SORF, 915 S. LaSalle Street, Box 2926, Duke University Medical Center, Durham, NC 27710

AT A GLANCE

Credentials
1. Education

Academic Experience
1. Current Appointments & Affiliations
2. Previous Appointments & Affiliations

Expertise

Research
1. Selected Grants

Publications
1. Selected Publications

Artistic Works / Events

Teaching

Advising & Mentoring

Recognition

Professional Activities

Manage Profile

Embed Profile Data

Selected Grants

Neutralizing Antibody Assessment for UVAX-HIV-101 Human Clinical Trial Study

ResearchPrincipal Investigator · Awarded by Uvax Bio, LLC · 2024 - 2026

CIVICs A - Option 18C

ResearchCo Investigator · Awarded by National Institutes of Health · 2022 - 2025

HHSN272201800004C-Option 13

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2021 - 2025

Nonhuman Primate Option 6

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2025

A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years

ResearchCo Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2024

Neutralizing Antibody Assessment for UVAX-HIV-101 Human Clinical Trial Study

ResearchPrincipal Investigator · Awarded by Uvax Bio, LLC · 2024 - 2026

CIVICs A - Option 18C

ResearchCo Investigator · Awarded by National Institutes of Health · 2022 - 2025

HHSN272201800004C-Option 13

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2021 - 2025

Nonhuman Primate Option 6

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2025

A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years

ResearchCo Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2024

Moderna mRNA1275 P205 Trial Neutralizing Antibody Assessment

ResearchCo Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2024

A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled, Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effe

ResearchCo Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2023

CIVICs A - Option 18B SAVE Aim 3

ResearchInvestigator · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2023

A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls

ResearchCo Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2023

Neutralizing Antibody Response Assessment for a Phase 2/3 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccin

ResearchCo Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2023

Nonhuman Primate Option 18

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2023

GH-VAP: Duke Antibody Dynamics Core Extension; INV-008612 Supplement

ResearchInvestigator · Awarded by Bill and Melinda Gates Foundation · 2019 - 2022

Characterizing the Neutralizing Antibody Response in SARS-CoV-2 Infected Individuals

ResearchPrincipal Investigator · Awarded by Rush University Medical Center · 2020 - 2022

A PHASE 2a, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF MRNA-1273 SARS-COV-2 VACCINE IN ADULTS AGED 18 YEARS A

ResearchCo Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2022

CIVICs A - Option 18A SAVE Aims 1, 2

ResearchCo Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2022

CoVPN 5001 A prospective study of acute immune responses to SARS-CoV2 infection - LAB

ResearchInvestigator · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2022

Sublingual-parenteral vaccination to prevent oral HIV transmission in infants

ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2018 - 2021

Harnessing Mucin-IgG Interactions to Enhance HIV Vaccine Function

ResearchInvestigator · Awarded by Northwestern University · 2020 - 2021

Comparing HIV Mucosal Targets in US and Kenyan Populations

ResearchInvestigator · Awarded by Northwestern University · 2019 - 2021

Primate Contract Expansion for Covid-19

ResearchInvestigator · Awarded by National Institutes of Health · 2020 - 2021

HVTN Laboratory Center: HVTN Phase 1

ResearchInvestigator · Awarded by Fred Hutchinson Cancer Research Center · 2015 - 2020

Nonhuman Primate Option 22

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2020

Antibody and viral determinants of protection against CMV infection in the gB/MF59 vaccination cohort

FellowshipPreceptor · Awarded by National Institutes of Health · 2017 - 2020

HVTN Laboratory Center: HVTN 117

ResearchAssistant Research Professor · Awarded by Fred Hutchinson Cancer Research Center · 2017 - 2018

HVTN Laboratory Center: HVTN 118

ResearchAssistant Research Professor · Awarded by Fred Hutchinson Cancer Research Center · 2017 - 2018

HVTN - A004

ResearchAssistant Research Professor · Awarded by Fred Hutchinson Cancer Research Center · 2015 - 2018

HIV Vaccine Trials Network: LC P5 PF

ResearchAssistant Research Professor · Awarded by Fred Hutchinson Cancer Research Center · 2015 - 2018

Nonhuman Primate Core-Option 6

ResearchResearch Associate · Awarded by National Institutes of Health · 2012 - 2018

HIV Vaccine Trials Network: LC P5 PF

ResearchResearch Associate · Awarded by Fred Hutchinson Cancer Research Center · 2014 - 2015

HVTN 505 Protocol

ResearchResearch Associate · Awarded by Fred Hutchinson Cancer Research Center · 2014 - 2015

LC: HIV Vaccine Trials Network: Phase 1 PF

ResearchResearch Associate · Awarded by Fred Hutchinson Cancer Research Center · 2014 - 2015

Enhancing protective antibody responses for a GM-CSF adjuvanted HIV vaccine

ResearchPrincipal Investigator · Awarded by GeoVax Inc · 2014 - 2015

Testing the ability of antibody-mucin interactions to provide vaccine function

ResearchMedical Monitor · Awarded by Northwestern University · 2013 - 2015